- Rapid Sequential Gain of ABL1 Kinase Domain Mutations with a Complex Karyotype in the Progression of Chronic Myelogenous Leukemia
-
Chung Y, Eom HS, Lee H, Park S, Shim H, Cho EH, Kong SY
- KMID: 1791958
- Ann Lab Med.
- 2014 Sep;34(5):399-401.
- doi: 10.3343/alm.2014.34.5.399
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Current Status of Molecular Targeted Therapies in Hepatocellular Carcinoma
-
Suh SJ, Yim HJ
- KMID: 1501636
- Korean J Gastroenterol.
- 2013 Mar;61(3):136-146.
- doi: 10.4166/kjg.2013.61.3.136
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in Korea. Curative treatment is only possible when the disease is diagnosed at the early stage. The prognosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer
-
Ryu JK
- KMID: 2373330
- Korean J Gastroenterol.
- 2015 Sep;66(3):150-153.
- doi: 10.4166/kjg.2015.66.3.150
Pancreatic adenocarcinoma is one of the fatalist malignancies. A large proportion of patients are diagnosed with unresectable stage pancreatic cancer at the time of presentation. Gemcitabine is a standard chemotherapeutic... -
- CITED
-
- Close
- SHARE
-
- Close
- Molecular targeted therapy for advanced gastric cancer
-
Kim JG
- KMID: 1501767
- Korean J Intern Med.
- 2013 Mar;28(2):149-155.
- doi: 10.3904/kjim.2013.28.2.149
Although medical treatment has been shown to improve quality of life and prolong survival, no significant progress has been made in the treatment of advanced gastric cancer (AGC) within the... -
- CITED
-
- Close
- SHARE
-
- Close
- Newer treatments for advanced hepatocellular carcinoma
-
Song MJ, Bae SH
- KMID: 1792028
- Korean J Intern Med.
- 2014 Mar;29(2):149-155.
- doi: 10.3904/kjim.2014.29.2.149
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The only curative treatment modalities for HCC are surgery, percutaneous ablation, and liver transplantation. Unfortunately, the majority of patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma
-
Lee HY, Lee KH, Hyun MS, Kim MK, Koh SA, Cho HS
- KMID: 1792044
- Korean J Intern Med.
- 2014 Mar;29(2):250-252.
- doi: 10.3904/kjim.2014.29.2.250
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells
-
Chang H, Sung JH, Moon SU, Kim HS, Kim JW, Lee JS
- KMID: 2374183
- Yonsei Med J.
- 2017 Jan;58(1):9-18.
- doi: 10.3349/ymj.2017.58.1.9
PURPOSE: Rearrangement of the proto-oncogene rearranged during transfection (RET) has been newly identified potential driver mutation in lung adenocarcinoma. Clinically available tyrosine kinase inhibitors (TKIs) target RET kinase activity, which... -
- CITED
-
- Close
- SHARE
-
- Close
- Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy
-
Sazuka T, Nihei N, Nakamura K, Sakamoto S, Fukasawa S, Komaru A, Ueda T, Igarashi T, Ichikawa T
- KMID: 2133288
- Korean J Urol.
- 2015 Mar;56(3):205-211.
- doi: 10.4111/kju.2015.56.3.205
PURPOSE: Single-agent interferon (IFN) is no longer regarded as a standard option for first-line systemic treatment of metastatic renal cell carcinoma (RCC) in Western countries. However, some patients with favorable-risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemotherapy for Pancreatic Cancer
-
Kim YT
- KMID: 782973
- Korean J Gastroenterol.
- 2008 Feb;51(2):111-118.
Chemotherapy is expected to play an important role in the treatment of pancreatic cancer because most of pancreatic cancers are being discovered at locally advanced or metastatic stages and recurrence... -
- CITED
-
- Close
- SHARE
-
- Close
- Frontier of Epilepsy Research - mTOR signaling pathway
-
Cho CH
- KMID: 1009965
- Exp Mol Med.
- 2011 May;43(5):231-274.
- doi: 10.3858/emm.2011.43.5.032
Studies of epilepsy have mainly focused on the membrane proteins that control neuronal excitability. Recently, attention has been shifting to intracellular proteins and their interactions, signaling cascades and feedback regulation... -
- CITED
-
- Close
- SHARE
-
- Close
- Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers
-
Wei H, Lu W, Li M, Zhang Q, Lu S
- KMID: 2466351
- Yonsei Med J.
- 2016 Jan;57(1):50-57.
- doi: 10.3349/ymj.2016.57.1.50
PURPOSE: Traditional chemotherapy is the main adjuvant therapy for the treatment of non-small cell lung cancer (NSCLC). However, the emergence of multi-drug resistance (MDR) has greatly restricted the curative effect... -
- CITED
-
- Close
- SHARE
-
- Close
- Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
-
Jeong JH, Cho BC, Shim HS, Kim HR, Lim SM, Kim SK, Chung KY, Islam SM, Song JJ, Kim SY, Kim JH
- KMID: 1777495
- J Korean Med Sci.
- 2013 Jul;28(7):1005-1014.
- doi: 10.3346/jkms.2013.28.7.1005
Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-kappaB). We investigated the association of non-small cell lung... -
- CITED
-
- Close
- SHARE
-
- Close
- Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
-
Hong J, Kyung SY, Lee SP, Park JW, Jung SH, Lee JI, Park SH, Sym SJ, Park J, Cho EK, Shin DB, Lee JH
- KMID: 1776611
- Korean J Intern Med.
- 2010 Sep;25(3):294-300.
- doi: 10.3904/kjim.2010.25.3.294
BACKGROUND/AIMS: The efficacy and safety of pemetrexed, gefitinib, and erlotinib administration in previously treated patients with non-small cell lung cancer (NSCLC) were compared. METHODS: The study patients met the following... -
- CITED
-
- Close
- SHARE
-
- Close
- Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung
-
Park SH, Ha SY, Lee JI, Lee H, Sim H, Kim YS, Hong J, Park J, Cho EK, Shin DB, Lee JH
- KMID: 1779162
- J Korean Med Sci.
- 2009 Jun;24(3):448-452.
- doi: 10.3346/jkms.2009.24.3.448
Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) have been reported to be related to certain clinical characteristics (i.e., female, non-smokers with adenocarcinoma) and gefitinib responsiveness.... -
- CITED
-
- Close
- SHARE
-
- Close
